Plenary Speakers

Volker Brinkmann, PhD
Sr Research Investigator,  Autoimmunity & Transplantation 
Novartis Institute for BioMedical Research 
Basel Switzerland 
Email: volker.brinkmann@pharma.novartis.com 
Fingolimod (FTY720) as a treatment of human Multiple Sclerosis - New mechnistic insights
  
Stephen W. Fesik, PhD
Professor of Biochemistry and Pharmacology
School of Medicine
Vanderbilt University
Nashville, TN
Email: stephen.fesik@vanderbilt.edu
Fragment-based cancer drug discovery
  
Edward J. Goetzl, MD 
University of California, San Francisco
Robert L. Kroc Professor, Department of Medicine
Professor, Department of Microbiology and Immunology
San Francisco, CA
Email: egoetzl@itsa.ucsf.edu
Diverse immunological effects of sphingolipids
 
Catherine Godson, PhD
Professor of Molecular Medicine
Director of UCD Diabetes Research Centre
University College Dublin
Belfield, Dublin, Ireland
Email: catherine.godson@ucd.ie 
Lipoxins: promoting resolution, suppressing fibrosis?
  
Lawrence J. Marnett, PhD
Vanderbilt University School of Medicine
Mary Geddes Stahlman Professor of Cancer Research
Professor of Biochemistry, Chemistry, and Pharmacology
Director-Vanderbilt Institute of Chemical Biology 
Nashville TN 
Email:  larry.marnett@vanderbilt.edu
COX-2 Oxygenation of Endocannabinoids:  2-Arachidonoylglycerol as a Precursor of Bioactive Eicosanoids and a Probe of COX Inhibition Mechanisms

 
Zena Werb, PhD
University of California, San Francisco
Professor and Vice-Chair, Dept of Anatomy
San Francisco, CA
Email:  zena.werb@ucsf.edu
Role of the dynamic microenvironment in tumor progression